Sucampo Pharmaceuticals, Inc. SCMP
Set alert
No live quote for SCMP yet.
- Open
- 18.00
- Prev close
- 18.00
- Mkt cap
- 847.54M
- Vol
- 303.07K
- Avg vol
- 3.45M
- EPS
- -3.37
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.95
- High
- 18.08
- Forward P/E
- 13.04
- Beta
- 0.58
- Short ratio
- 9.78
- Inst. own
- 82.47%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 17.99
- 200-d avg
- 13.81
- 1y target
- 17.40
Analyst view
Consensus: hold
Hold
Price target (mean) 17.40
- Target (low)
- 15.00
- Target (mean)
- 17.40
- Target (high)
- 18.00
Ratings (0m) 8 5 buy · 2 hold · 1 sell
- Strong buy1
- Buy4
- Hold2
- Sell1
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 6
- 2 months ago 7
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.35 | 0.32 – 0.37 | 0.68 | -48.5% | 75.59M | +3.5% | 4 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.23 | 0.0% | 58.82M | +4.5% | 0 |
| Current year | 1.12 | 1.09 – 1.15 | 1.51 | -25.8% | 252.91M | +9.9% | 3 |
| Next year | 1.38 | 1.10 – 1.90 | 1.12 | +23.2% | 263.30M | +4.1% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 25, 2018 | Nomura | Downgrade | Buy | Neutral |
| Jan 1, 2018 | Leerink Swann | Downgrade | Outperform | Market Perform |
| Dec 26, 2017 | Maxim Group | Downgrade | Buy | Hold |
| Dec 25, 2017 | B. Riley | Downgrade | Buy | Neutral |
| Dec 18, 2017 | Instinet | Initiated | — | Buy |
| Nov 13, 2017 | B. Riley | Initiated | — | Buy |
| Oct 2, 2017 | Mizuho | Downgrade | Buy | Neutral |
| Aug 20, 2017 | Leerink Swann | Initiated | — | Outperform |
| Dec 21, 2016 | Mizuho | Upgrade | — | Buy |
| Sep 6, 2016 | Northland Securities | Initiated | — | Outperform |
| Aug 3, 2016 | Mizuho | Downgrade | — | Neutral |
| Apr 19, 2016 | Mizuho | Upgrade | — | Buy |
| Feb 8, 2016 | UBS | Initiated | — | Buy |
| Jan 11, 2016 | Empire Asset Management | Initiated | — | Sell |
| Nov 19, 2015 | Jefferies | Initiated | — | Hold |
| Oct 8, 2015 | Mizuho | Initiated | — | Neutral |
| Aug 23, 2015 | H.C. Wainwright | Initiated | — | Buy |
| May 6, 2015 | Cantor Fitzgerald | Downgrade | — | Hold |
| Apr 7, 2015 | Guggenheim | Initiated | — | Buy |
| Apr 5, 2015 | Guggenheim | Initiated | — | Buy |
| Mar 1, 2015 | Credit Suisse | Downgrade | — | Underperform |
| Oct 9, 2014 | Maxim Group | Upgrade | — | Buy |
| Sep 29, 2014 | Wallachbeth | Initiated | — | Buy |
| Jul 31, 2014 | Roth Capital | Initiated | — | Buy |
| Sep 2, 2013 | Maxim Group | Downgrade | — | Hold |
| Jun 20, 2013 | Credit Suisse | Initiated | — | Neutral |
| Apr 30, 2013 | McNicoll Lewis Vlak | Initiated | — | Buy |
| Apr 2, 2013 | Cantor Fitzgerald | Initiated | — | Buy |
| Mar 18, 2013 | Maxim Group | Initiated | — | Buy |